Jacobs Levy Equity Management, Inc Adverum Biotechnologies, Inc. Transaction History

Jacobs Levy Equity Management, Inc

$24.7 Billion
Q3 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	SELL	$0.96 - $9.68 $30,173 - $304,252	-31,431 Reduced 5.35%	556,214 $528,000
Q2 2022 Aug 15, 2022	SELL	$0.81 - $1.34 $682,511 - $1.13 Million	-842,607 Reduced 58.91%	587,645 $705,000
Q1 2022 May 16, 2022	BUY	$1.23 - $1.95 $507,382 - $804,386	412,506 Added 40.53%	1,430,252 $1.87 Million
Q4 2021 Feb 14, 2022	BUY	$1.74 - $2.4 $1.53 Million - $2.11 Million	878,142 Added 629.02%	1,017,746 $1.79 Million
Q3 2021 Nov 15, 2021	BUY	$2.08 - $3.6 $290,376 - $502,574	139,604 New	139,604 $303,000
Q4 2020 Feb 16, 2021	SELL	$9.84 - $14.26 $949,992 - $1.38 Million	-96,544 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$10.3 - $21.64 $104,534 - $219,624	-10,149 Reduced 9.51%	96,544 $994,000
Q2 2020 Aug 17, 2020	SELL	$8.53 - $25.64 $218,402 - $656,486	-25,604 Reduced 19.35%	106,693 $2.23 Million
Q1 2020 May 15, 2020	BUY	$7.98 - $16.32 $62,698 - $128,226	7,857 Added 6.31%	132,297 $1.29 Million
Q4 2019 Feb 14, 2020	BUY	$5.12 - $12.22 $365,772 - $872,996	71,440 Added 134.79%	124,440 $1.43 Million
Q3 2019 Nov 14, 2019	BUY	$5.24 - $15.89 $111,088 - $336,868	21,200 Added 66.67%	53,000 $289,000
Q2 2019 Aug 13, 2019	SELL	$5.1 - $11.89 $60,179 - $140,302	-11,800 Reduced 27.06%	31,800 $378,000
Q1 2019 May 14, 2019	SELL	$3.03 - $6.02 $168,870 - $335,512	-55,733 Reduced 56.11%	43,600 $228,000
Q4 2018 Feb 14, 2019	BUY	$2.87 - $5.92 $112,050 - $231,128	39,042 Added 64.76%	99,333 $313,000
Q3 2018 Nov 14, 2018	SELL	$4.5 - $7.6 $101,083 - $170,718	-22,463 Reduced 27.14%	60,291 $365,000
Q2 2018 Aug 14, 2018	BUY	$5.3 - $6.9 $68,173 - $88,754	12,863 Added 18.4%	82,754 $439,000
Q1 2018 May 15, 2018	SELL	$3.65 - $7.95 $68,255 - $148,665	-18,700 Reduced 21.11%	69,891 $405,000
Q4 2017 Feb 13, 2018	SELL	$2.85 - $3.95 $8,835 - $12,245	-3,100 Reduced 3.38%	88,591 $310,000
Q3 2017 Nov 14, 2017	BUY	$2.45 - $3.65 $23,765 - $35,405	9,700 Added 11.83%	91,691 $335,000
Q2 2017 Nov 09, 2017	BUY	N/A	81,991	81,991 $205,000

Others Institutions Holding ADVM

# of Institutions

Shares Held

524K

Call Options Held

Put Options Held

Versant Venture Management, LLC San Francisco, CA

507K
Shares

$2.29 Million
9.32% of portfolio
Pinz Capital Management, LP New York, NY

15.7K
Shares

$70,964
0.03% of portfolio
American Portfolios Advisors Holbrook, NY

1.15K
Shares

$5,197
0.0% of portfolio

View Full List

About Adverum Biotechnologies, Inc.

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $449M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

More about ADVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Account